Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases - Takeaways - MDSpire

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

  • By

  • Xiangke Xin

  • Wenli Zhang

  • Zhen Li

  • Ruirui Gui

  • Juan Wang

  • Liyun Ji

  • Yanli Zhang

  • Baijun Fang

  • Yongping Song

  • Yingling Zu

  • Jian Zhou

  • February 5, 2025

  • 0 min

Share

  • 1

    Anemia after allo-HSCT is common and can result from immune or non-immune factors, leading to significant complications.

  • 2

    Luspatercept is the first FDA-approved agent that enhances red blood cell maturation, showing efficacy in treating anemia in specific patient populations.

  • 3

    In a study of 16 patients, luspatercept significantly increased hemoglobin levels, with 81.3% achieving an erythroid response.

  • 4

    The treatment was well-tolerated, with only mild grade 1 toxicities reported and an overall survival rate of 93.8% among patients.

  • 5

    Further research is needed to explore luspatercept's efficacy in treating anemia associated with conditions like PRCA and PGF.

Original Source(s)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases

  • by Xiangke Xin, Wenli Zhang, Zhen Li, Ruirui Gui, Juan Wang, Liyun Ji, Yanli Zhang, Baijun Fang, Yongping Song, Yingling Zu, Jian Zhou

  • February 5, 2025

Related Content

Health-economic evaluation of a novel personalized digital avatar-based anemia management software in hemodialysis patients

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

  • 1 min
Correction to: “The Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Type 2 Diabetes-A Real-World Study”

  • August 26, 2025